Who is SurgMark?
We are a company specializing in innovative solutions in medical technology and biotechnology. Our team is interdisciplinary: the shareholders come from the fields of medicine, development and the start-up scene.
We have many years of industry experience, looking back on successful start-ups and product innovations. Our management team has executed several successful business exits in the form of trade sales for investors.
In this way, we combine expertise with a keen eye for market potential.
SurgMark is committed to developing innovative solutions for the diagnosis and therapy of breast cancer and other tumor diseases. With our latest tool SchurSign we combine know-how from breast surgery and biomaterial research.
Know-How in Medtec and Start ups:
SurgMark consists of experienced shareholders with various areas of expertise.
Learn more about us:
Dr. med Peter Meier (M.D.)
… is a serial entrepreneur and physician.
He is enthusiastic about the development of innovations.
Dr. med Frank Schure (M.D.)
… is over 30 years of experience in breast cancer treatment. In an award-winning partnership with Samsung, he is working on a tissue-sparing, ultrasound-assisted tumor resection.
Dr. med Rivelino Montenegro (PhD)
… is a chemist and repeatedly successful founder in the fields of medical technology, cosmetics and materials science.
Dr. rer. nat. Thomas Freier (D.Sc.)
… is a chemist, serial entrepreneur, and expert in medical devices and biomaterials.